NCT00683046View on ClinicalTrials.gov

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

PHASE2CompletedINTERVENTIONAL

Enrollment

204

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Acute Myelogenous LeukemiaLymphoid LeukemiaChronic Myelogenous LeukemiaMalignant LymphomaHodgkin's DiseaseChronic Lymphocytic LeukemiaMyeloproliferative DisorderAnemia, AplasticMyelodysplastic Syndromes

Interventions

DRUG

Fludarabine

Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.

DRUG

Melphalan

Melphalan 140 mg/m2 IV on day -2.

DRUG

Stem cells

Stem cell infusion on day 0.

DRUG

Campath

Campath, 20 mg IV on day -7, 6, -5, -4, and -3.

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors

lead

University of Chicago

OTHER

NCT00683046 - T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter